What medication can be added to Prozac (fluoxetine) and Effexor (venlafaxine) for a patient with treatment-resistant depression?

Augmentation Strategy for Treatment-Resistant Depression on Dual Antidepressants

Add an atypical antipsychotic—specifically aripiprazole starting at 2-5 mg daily—to your current regimen of Prozac and Effexor, as this represents the most evidence-based augmentation strategy for treatment-resistant depression with superior remission rates compared to switching or combining additional antidepressants. 1, 2

Primary Recommendation: Atypical Antipsychotic Augmentation

When two antidepressants from different classes have failed to achieve remission, the evidence strongly favors augmentation with atypical antipsychotics over adding a third antidepressant. 2, 3

Aripiprazole as First-Line Augmentation

• Start aripiprazole at 2 mg daily to minimize tremor and akathisia risk, then increase by 2-3 mg every 1-2 weeks as tolerated, targeting 10-15 mg daily. 1
• Aripiprazole demonstrates remission rates of 55.4% in treatment-resistant depression, which is substantially higher than antidepressant switching or combination strategies. 1
• This medication is FDA-approved specifically for augmentation in major depressive disorder. 2, 3

Alternative Atypical Antipsychotics

• Quetiapine extended-release (150-300 mg daily) is an effective alternative if aripiprazole causes intolerable akathisia or restlessness. 2, 3
• Brexpiprazole (1-3 mg daily) or cariprazine (1.5-3 mg daily) are newer options with potentially better tolerability profiles. 2
• The olanzapine-fluoxetine combination (6/25 mg to 12/50 mg daily) is FDA-approved but carries significant metabolic risks including weight gain and metabolic syndrome. 4, 2, 3

Secondary Strategy: Antidepressant Augmentation with Bupropion

If you prefer to avoid antipsychotics or if they fail, adding bupropion SR 150-300 mg daily to your current regimen is the next best option. 5, 1

• Bupropion augmentation decreases depression severity more effectively than buspirone augmentation in the STAR*D trial. 5, 1
• Critical drug interaction warning: Bupropion inhibits CYP2D6 and can significantly increase venlafaxine (Effexor) levels, potentially requiring dose reduction of Effexor. 6
• Monitor closely for serotonin syndrome symptoms (agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity) when combining these medications. 1

Why Not Add Another Antidepressant Class?

The STAR*D study demonstrated that after two antidepressant failures, the likelihood of remission with additional antidepressant switching drops dramatically. 1 You've already failed two different antidepressant classes (SSRI and SNRI), making augmentation strategies more appropriate than switching to a third antidepressant monotherapy. 1, 3

Critical Monitoring Requirements

• Weekly follow-up during the first month of augmentation to assess response and side effects. 1
• Monitor for akathisia, restlessness, and weight gain with atypical antipsychotics. 2, 3
• Screen for suicidal ideation at each visit, as treatment-resistant depression carries increased suicide risk. 1
• Check metabolic parameters (weight, glucose, lipids) at baseline and every 3 months if using olanzapine or quetiapine. 4, 2

Common Pitfalls to Avoid

• Do not add lithium or thyroid hormone (T3) as first-line augmentation—these are effective but require more intensive monitoring and are typically reserved for patients who fail atypical antipsychotic augmentation. 1, 3
• Avoid combining bupropion with MAOIs due to severe hypertension risk. 6
• Do not assume higher doses of your current antidepressants will work—you're likely already at therapeutic levels, and the issue is treatment resistance, not inadequate dosing. 1
• Avoid switching to venlafaxine monotherapy since you're already on Effexor (venlafaxine). 7

Treatment Algorithm Summary

1. First choice: Add aripiprazole 2-5 mg daily, titrate to 10-15 mg over 4-6 weeks 1, 2
2. Second choice: Add quetiapine XR 150-300 mg daily if aripiprazole not tolerated 2, 3
3. Third choice: Add bupropion SR 150-300 mg daily with careful monitoring for drug interactions 5, 1, 6
4. Fourth choice: Consider lithium augmentation (300 mg BID, target level 0.6-1.0 mEq/L) if all above fail 1

The evidence strongly supports moving to augmentation rather than switching at this stage of treatment resistance, with atypical antipsychotics showing the most robust efficacy data. 2, 3